GlassScriptPhysician profile
Samir N Vora
NPI 1376562629
$10,433.94
in general payments reported to CMS, 2019-2025
29 companies · $1,731 in 2025
The $1,731 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,291 · 2020: $963 · 2021: $1,470 · 2022: $1,394 · 2023: $1,178 · 2024: $1,407 · 2025: $1,731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,136 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,136.37 |
| Education | $179.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,342.06 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,612.18 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $1,467.79 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,291.60 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $823.09 | 2019-2024 | Xarelto |
| Genzyme Corporation | $362.79 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $324.98 | 2019-2024 | |
| Pfizer INC. | $318.66 | 2019-2025 | |
| Mylan Specialty L.P. | $241.28 | 2019-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $207.69 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $195.05 | 2021-2025 | Dupixent |
| Mallinckrodt Hospital Products INC. | $154.71 | 2021-2022 | |
| Genentech USA, INC. | $105.77 | 2019-2023 | Xolair |
| Amgen INC. | $93.50 | 2022-2025 | Tezspire |
| Boston Scientific Corporation | $92.88 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $89.50 | 2019 | |
| Merck Sharp & Dohme LLC | $87.70 | 2020-2022 | |
| Janssen Products, LP | $87.54 | 2019 | |
| Amarin Pharma, INC. | $85.94 | 2019 | |
| Livanova USA, INC. | $84.38 | 2019 | |
| Philips North America LLC | $78.99 | 2024-2025 | Vest Therapy Und, (8874) Incourage |
| Gilead Sciences, INC. | $77.66 | 2019 | |
| Verona Pharma, INC. | $57.58 | 2025 | Ohtuvayre |
| Insmed, INC. | $38.32 | 2024-2025 | Arikayce |
| United Therapeutics Corporation | $33.73 | 2024 | Tyvaso |
| Sunovion Pharmaceuticals INC. | $25.25 | 2020 | |
| Viatris Specialty LLC | $24.57 | 2025 | Yupelri |
| Novo Nordisk INC | $16.21 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samir Vora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.